NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. The full ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sage Therapeutics stock opened at $7.44 on Friday. The business’s 50-day simple moving average is $5.64 and its 200 day simple moving average is $7.53. The stock has a market cap of $455.13 ...

Fraser Murray, PhD, CEO, Pheno Therapeutics. Image Credit: Pheno Therapeutics A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to ...

Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session.

For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own. The bid of $7.22 per share was a 30% premium to ...